Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG(4) response

BACKGROUND: BM32, a grass pollen allergy vaccine containing four recombinant fusion proteins consisting of hepatitis B-derived PreS and hypoallergenic peptides from the major timothy grass pollen allergens adsorbed on aluminium hydroxide has been shown to be safe and to improve clinical symptoms of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:EBioMedicine
Autors principals: Eckl-Dorna, Julia, Weber, Milena, Stanek, Victoria, Linhart, Birgit, Ristl, Robin, Waltl, Eva E., Villazala-Merino, Sergio, Hummel, Andrea, Focke-Tejkl, Margarete, Froeschel, Renate, Neubauer, Angela, Henning, Rainer, Perkmann, Thomas, Valenta, Rudolf, Niederberger, Verena
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2019
Matèries:
Research paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6921329/
https://ncbi.nlm.nih.gov/pubmed/31786130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.11.006
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars